Arenas A, Ayala R, Gallardo M, et al. Ruxolitinib/nilotinib/prednisoline combination: a promising novel treatment for myelofibrosis. EHA 2017, abstract P695.,Arenas A, Ayala RM, Linares M, et al. Nilotinib plus ruxolitinib produces anti-fibrotic effect. Blood. 2016;128:5497.
MRD-status 1 jaar na stamceltransplantatie geassocieerd met overleving na 6 jaar
jun 2024 | MM, Stamceltransplantatie